Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 300

1.

Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?

Evans M, Rees A.

Drug Saf. 2002;25(9):649-63. Review.

PMID:
12137559
2.

Statins and myotoxicity: a therapeutic limitation.

Tiwari A, Bansal V, Chugh A, Mookhtiar K.

Expert Opin Drug Saf. 2006 Sep;5(5):651-66. Review.

PMID:
16907655
3.

HMG-CoA reductase inhibitors and myotoxicity.

Ucar M, Mjörndal T, Dahlqvist R.

Drug Saf. 2000 Jun;22(6):441-57. Review.

PMID:
10877038
4.

The myotoxicity of statins.

Evans M, Rees A.

Curr Opin Lipidol. 2002 Aug;13(4):415-20. Review.

PMID:
12151857
5.

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Williams D, Feely J.

Clin Pharmacokinet. 2002;41(5):343-70. Review.

PMID:
12036392
6.

Rhabdomyolysis and statin therapy: relevance to the elderly.

Sica DA, Gehr TW.

Am J Geriatr Cardiol. 2002 Jan-Feb;11(1):48-55. Review.

PMID:
11773716
7.

Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.

Jamal SM, Eisenberg MJ, Christopoulos S.

Am Heart J. 2004 Jun;147(6):956-65. Review.

PMID:
15199341
8.

Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.

Chang JT, Staffa JA, Parks M, Green L.

Pharmacoepidemiol Drug Saf. 2004 Jul;13(7):417-26.

PMID:
15269925
9.

Statin-associated myopathy.

Thompson PD, Clarkson P, Karas RH.

JAMA. 2003 Apr 2;289(13):1681-90. Review.

PMID:
12672737
10.

Safety considerations for statins.

Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R.

Curr Opin Lipidol. 2002 Dec;13(6):637-44. Review.

PMID:
12441888
11.

Statin-fibrate combination therapy.

Shek A, Ferrill MJ.

Ann Pharmacother. 2001 Jul-Aug;35(7-8):908-17. Review.

PMID:
11485144
13.

Statins and myotoxicity.

Farmer JA.

Curr Atheroscler Rep. 2003 Mar;5(2):96-100. Review.

PMID:
12573193
14.

[Safety profile of statins].

Prieto JC.

Rev Med Chil. 2001 Nov;129(11):1237-40. Spanish.

PMID:
11836874
15.
16.

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.

Jones PH, Davidson MH.

Am J Cardiol. 2005 Jan 1;95(1):120-2.

PMID:
15619408
17.

Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD.

Drug Saf. 2010 Mar 1;33(3):171-87. doi: 10.2165/11319380-000000000-00000. Review.

PMID:
20158283
18.

Rhabdomyolysis and HMG-CoA reductase inhibitors.

Omar MA, Wilson JP, Cox TS.

Ann Pharmacother. 2001 Sep;35(9):1096-107. Review. Erratum in: Ann Pharmacother 2001 Oct;35(10):1296.

PMID:
11573861
19.

Statin safety and drug interactions: clinical implications.

Bottorff MB.

Am J Cardiol. 2006 Apr 17;97(8A):27C-31C. Epub 2006 Jan 25. Review.

PMID:
16581325
20.

Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.

Nishimoto T, Ishikawa E, Anayama H, Hamajyo H, Nagai H, Hirakata M, Tozawa R.

Toxicol Appl Pharmacol. 2007 Aug 15;223(1):39-45. Epub 2007 May 24.

PMID:
17599378
Items per page

Supplemental Content

Write to the Help Desk